CHRDL1

Across TCGA pan-cancer cohorts, CHRDL1 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CHRDL1 data layer compared with 21 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher CHRDL1 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated CHRDL1 expression acts as an unfavorable survival marker, although some lineages such as HNSC and LSCC show a favorable association.

HNSC, PDAC, and LUAD are the cancer types where CHRDL1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	III,IV	0.960	0.750	.005	27	view →
PDAC	DFS	Quartile	III,IV	0.196	0.998	.024	8	view →
LUAD	OS	Median	III,IV	0.333	0.897	.013	8	view →
CCRCC	DFS	Tertile	All	0.515	1.000	.024	4	view →
LSCC	DFS	Median	II,III,IV	1.000	0.571	.030	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

CHRDL1–HNSC (OS)

Open the HNSC breakdown →